News >

Flinn Sheds Light on Advances in MCL and Other Lymphomas

Danielle Bucco
Published: Tuesday, Mar 06, 2018

Ian W. Flinn, MD, PhD

Ian W. Flinn, MD, PhD
The FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta) in October 2017 for patients with non-Hodgkin lymphoma was one of the most exciting advancements in years for the lymphoma community.

Investigators are building on this breakthrough by exploring combination regimens with the CAR T-cell therapy. Results from the phase I/II ZUMA-6 trial presented at the 2017 ASH Annual Meeting showed that the combination of axi-cel with the PD-L1 inhibitor atezolizumab (Tecentriq) was highly active with a manageable safety profile in patients with refractory diffuse large B-cell lymphoma (DLBCL).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication